BioCentury | Oct 13, 2014
Clinical News

Simdax levosimendan: Phase III started

...Simdax is approved in over 50 countries to treat acutely decompensated heart failure. Tenax (formerly Oxygen Biotherapeutics Inc....
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

...of tecemotide monotherapy for NSCLC after the compound failed in a Japanese Phase I/II trial Oxygen Biotherapeutics Inc....
BioCentury | Sep 15, 2014
Clinical News

Oxycyte: Phase IIb halted

...its merger with Phyxius Pharma Inc. (see BioCentury, Oct. 28, 2013 & Nov. 23, 2013). Oxygen Biotherapeutics Inc....
BioCentury | Sep 12, 2014
Company News

Oxygen slides on Oxycyte trial halt

Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) fell $0.36 to $3.70 in early after-hours trading on Thursday after announcing it would halt a Phase IIb trial evaluating Oxycyte to treat traumatic brain injury. Oxygen said it had difficulties...
BioCentury | Sep 1, 2014
Clinical News

Simdax levosimendan: Phase IIb ongoing

...begin Phase III testing of the product in 3Q14. Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland Oxygen Biotherapeutics Inc....
BioCentury | Apr 7, 2014
Finance

2Q14 Financial Markets Preview: Minor adjustment

...NYSE-M:NBY) 3/20/14 $6.7 $60.3 $58.8 -3% Sangamo BioSciences Inc. (NASDAQ:SGMO) 3/20/14 $100.0 $1,500.5 $1,205.7 -20% Oxygen Biotherapeutics Inc....
BioCentury | Mar 24, 2014
Finance

Highlights of weekly biotech stock moves

...hafnium oxide activated in vivo via standard radiation therapy. Nanobiotix gained €0.25 on the week. Oxygen Biotherapeutics Inc....
BioCentury | Mar 24, 2014
Financial News

Oxygen Biotherapeutics completes follow-on

Oxygen Biotherapeutics Inc. (NASDAQ:OXBT), Morrisville, N.C. Business: Hematology, Diagnostic, Pulmonary Date completed: 3/18/14 Type: Follow-on Raised: $52 million Shares: 9.3 million Price: $5.60 Shares after offering: 26.4 million Underwriters: Ladenburg Thalmann; MTS Securities Overallotment: 1.4...
BioCentury | Mar 19, 2014
Financial News

Oxygen raises $52 million in follow-on

Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) raised $52 million through the sale of 9.3 million shares at $5.60 in a follow-on underwritten by Ladenburg Thalmann and MTS Securities. Oxygen proposed the offering late Monday, when its share...
BioCentury | Nov 25, 2013
Company News

Orion, Oxygen Biotherapeutics, Phyxius deal

...became EVP of regulatory affairs (see BioCentury, Oct. 21). Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland Oxygen Biotherapeutics Inc....
Items per page:
1 - 10 of 99
BioCentury | Oct 13, 2014
Clinical News

Simdax levosimendan: Phase III started

...Simdax is approved in over 50 countries to treat acutely decompensated heart failure. Tenax (formerly Oxygen Biotherapeutics Inc....
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

...of tecemotide monotherapy for NSCLC after the compound failed in a Japanese Phase I/II trial Oxygen Biotherapeutics Inc....
BioCentury | Sep 15, 2014
Clinical News

Oxycyte: Phase IIb halted

...its merger with Phyxius Pharma Inc. (see BioCentury, Oct. 28, 2013 & Nov. 23, 2013). Oxygen Biotherapeutics Inc....
BioCentury | Sep 12, 2014
Company News

Oxygen slides on Oxycyte trial halt

Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) fell $0.36 to $3.70 in early after-hours trading on Thursday after announcing it would halt a Phase IIb trial evaluating Oxycyte to treat traumatic brain injury. Oxygen said it had difficulties...
BioCentury | Sep 1, 2014
Clinical News

Simdax levosimendan: Phase IIb ongoing

...begin Phase III testing of the product in 3Q14. Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland Oxygen Biotherapeutics Inc....
BioCentury | Apr 7, 2014
Finance

2Q14 Financial Markets Preview: Minor adjustment

...NYSE-M:NBY) 3/20/14 $6.7 $60.3 $58.8 -3% Sangamo BioSciences Inc. (NASDAQ:SGMO) 3/20/14 $100.0 $1,500.5 $1,205.7 -20% Oxygen Biotherapeutics Inc....
BioCentury | Mar 24, 2014
Finance

Highlights of weekly biotech stock moves

...hafnium oxide activated in vivo via standard radiation therapy. Nanobiotix gained €0.25 on the week. Oxygen Biotherapeutics Inc....
BioCentury | Mar 24, 2014
Financial News

Oxygen Biotherapeutics completes follow-on

Oxygen Biotherapeutics Inc. (NASDAQ:OXBT), Morrisville, N.C. Business: Hematology, Diagnostic, Pulmonary Date completed: 3/18/14 Type: Follow-on Raised: $52 million Shares: 9.3 million Price: $5.60 Shares after offering: 26.4 million Underwriters: Ladenburg Thalmann; MTS Securities Overallotment: 1.4...
BioCentury | Mar 19, 2014
Financial News

Oxygen raises $52 million in follow-on

Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) raised $52 million through the sale of 9.3 million shares at $5.60 in a follow-on underwritten by Ladenburg Thalmann and MTS Securities. Oxygen proposed the offering late Monday, when its share...
BioCentury | Nov 25, 2013
Company News

Orion, Oxygen Biotherapeutics, Phyxius deal

...became EVP of regulatory affairs (see BioCentury, Oct. 21). Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland Oxygen Biotherapeutics Inc....
Items per page:
1 - 10 of 99